Evidence map›Paper›PMID 34862480›Full record

ReviewNature reviews. Drug discovery2022

Targeting cancer metabolism in the era of precision oncology.

Zachary E Stine, Zachary T Schug, Joseph M Salvino, Chi V Dang

Open access · bronzeAbstract readReview
In one paragraph

Review in Nature reviews. Drug discovery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 704 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
704citing papers in PubMed, 1 pooled it
68.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

704 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,127 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

644 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Zachary E StineBarer Institute 520 Broad Street, Newark, NJ, USA.
Zachary T SchugThe Wistar Institute Philadelphia, Philadelphia, PA, USA.ORCID 0000-0003-4197-8227
Joseph M SalvinoThe Wistar Institute Philadelphia, Philadelphia, PA, USA.ORCID 0000-0002-2184-5980
Chi V DangThe Wistar Institute Philadelphia, Philadelphia, PA, USA. cdang@lcr.org.ORCID 0000-0002-4031-2522
The Wistar Institute · US

Funding

Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Targeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI AMARAVADI, RAVI K · 2008 to 2023
$37.1M
C-MYC TARGETS IN THE PATHOGENESIS OF HUMAN CANCERSR01CA057341 · NCI · WISTAR INSTITUTE · PI DANG, CHI V. · 1992 to 2021
$8.3M
MYC--TRANSCRIPTION AND INTERACTION WITH P107R01CA051497 · NCI · WISTAR INSTITUTE · PI DANG, CHI V. · 1995 to 2025
$5.3M
C MYC--TRANSCRIPTION AND APOPTOSISR37CA051497 · NCI · JOHNS HOPKINS UNIVERSITY · PI DANG, CHI V. · 1999 to 2006
$2.8M
Defining metabolic adaptations within the PDAC "arid" tumor microenvironmentR01CA252225 · NCI · WISTAR INSTITUTE · PI DANG, CHI V., STANGER, BEN Z · 2021 to 2025
$2.8M
The multifaceted role of acetate in cancerDP2CA249950 · NCI · WISTAR INSTITUTE · PI SCHUG, ZACHARY T · 2019 to 2019
$2.7M
NCI NIH HHS DP2 CA249950NCI NIH HHS P01 CA114046NCI NIH HHS P30 CA010815NCI NIH HHS R01 CA051497NCI NIH HHS R01 CA057341NCI NIH HHS R01 CA252225NCI NIH HHS R37 CA051497
6 · The paper itself

Abstract

One hundred years have passed since Warburg discovered alterations in cancer metabolism, more than 70 years since Sidney Farber introduced anti-folates that transformed the treatment of childhood leukaemia, and 20 years since metabolism was linked to oncogenes. However, progress in targeting cancer metabolism therapeutically in the past decade has been limited. Only a few metabolism-based drugs for cancer have been successfully developed, some of which are in - or en route to - clinical trials. Strategies for targeting the intrinsic metabolism of cancer cells often did not account for the metabolism of non-cancer stromal and immune cells, which have pivotal roles in tumour progression and maintenance. By considering immune cell metabolism and the clinical manifestations of inborn errors of metabolism, it may be possible to isolate undesirable off-tumour, on-target effects of metabolic drugs during their development. Hence, the conceptual framework for drug design must consider the metabolic vulnerabilities of non-cancer cells in the tumour immune microenvironment, as well as those of cancer cells. In this Review, we cover the recent developments, notable milestones and setbacks in targeting cancer metabolism, and discuss the way forward for the field.

Indexed as

Energy MetabolismMolecular Targeted TherapyPrecision MedicineAnimalsHumansMetabolism, Inborn ErrorsNeoplasms

Identifiers

PMID34862480
PMCPMC8641543
OpenAlexW3217589610

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.